HIGHLIGHTS
- who: D.V.T. Catenacci from the Department of Medicine, The University of Chicago Medical Centre, Chicago, USA have published the research: Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A, in the Journal: (JOURNAL) of 15/Oct/2019
- what: The study was designed to move to cohort A part 2 if the interim analysis, conducted on 40 patients in the responsible evaluable population, passed the prespecified futility border represented by at least 21 (53%) responders (complete response or partial response) per independent review, and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.